Rashid Hussain | Genetic Engineering | Best Innovation Award

Published on by New Scientists

Best Innovation Award

Rashid Hussain
Karakoram International University , Pakistan
Rashid Hussain
Affiliation Karakoram International University
Country Pakistan
Scopus ID 58102963300
Documents 9
Citations 68
h-index 4
Subject Area Genetic Engineering
Event New Scientists Awards
ORCID 0000-0003-3260-7280

Rashid Hussain recognizes the Best Innovation Award  who demonstrate notable contributions to scientific advancement through innovative research and scholarly activities. Rashid Hussain has contributed to the field of Genetic Engineering through research addressing contemporary challenges in biotechnology, molecular genetics, and applied life sciences. His academic output and citation record reflect active engagement with emerging scientific questions and interdisciplinary research initiatives.[1]

Abstract

Genetic Engineering continues to play a pivotal role in advancing biotechnology, agriculture, medicine, and environmental sustainability. Rashid Hussain’s research portfolio demonstrates engagement with molecular approaches aimed at understanding biological systems and developing innovative applications. His scholarly work contributes to the broader scientific effort to improve genetic technologies and their practical implementation.[2]

Keywords

Genetic Engineering, Biotechnology, Molecular Genetics, Genome Research, Gene Expression, Biological Innovation, Applied Biotechnology, Scientific Research.

Introduction

The rapid evolution of genetic technologies has transformed modern biological sciences. Researchers working within this domain contribute to advances in healthcare, agriculture, and environmental management. Rashid Hussain’s academic activities are aligned with these developments through investigations that support scientific understanding and practical applications of genetic engineering methodologies.[3]

Research Profile

Affiliated with Karakoram International University, Rashid Hussain has established a research profile focused on biotechnology and genetic engineering. His scholarly record includes peer-reviewed publications indexed in international databases. Through collaborative and interdisciplinary research, he has contributed to the dissemination of scientific knowledge within his field.[1]

Research Contributions

  • Research contributions in genetic engineering and biotechnology.
  • Participation in studies involving molecular and cellular biological systems.
  • Support for scientific innovation through experimental and analytical methodologies.
  • Contribution to academic literature and research dissemination.
  • Engagement with interdisciplinary scientific collaborations.

Publications

The researcher’s publication record includes articles addressing topics related to biotechnology, genetic engineering, and molecular research. These publications contribute to the scientific community’s understanding of biological processes and innovative genetic methodologies.[4]

Research Impact

With 68 citations and an h-index of 4, the available bibliometric indicators suggest measurable scholarly influence within the research community. Citation metrics provide evidence that published work has been referenced by other researchers, supporting knowledge exchange and scientific development.[1]

Award Suitability

The Best Innovation Award acknowledges individuals whose research demonstrates originality, scientific relevance, and commitment to advancing knowledge. Rashid Hussain’s work in Genetic Engineering aligns with these objectives through scholarly contributions, publication activity, and participation in contemporary scientific research initiatives.[5]

Conclusion

Rashid Hussain represents an emerging contributor within the field of Genetic Engineering. His research activities, publication record, and scholarly engagement support ongoing scientific progress and reflect the qualities recognized by innovation-focused academic awards.

References

  1. Elsevier. (n.d.). Scopus author details: Rashid Hussain, Author ID 58102963300. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=58102963300
  2. National Human Genome Research Institute. (n.d.). Genetic Engineering Overview.
    https://www.genome.gov/
  3. Nature Biotechnology. (2015). Advances in Genome Engineering.
    https://doi.org/10.1038/nbt.3121
  4. National Center for Biotechnology Information. (n.d.). Biotechnology and Molecular Research Resources.
    https://www.ncbi.nlm.nih.gov/
  5. New Scientists Awards. (n.d.). Award Recognition and Evaluation Framework.
    https://newscientists.net/

Xiaoquan Huang | Health and Medicine Advances | Research Excellence Award

Published on by New Scientists

Dr. Xiaoquan Huang | Health and Medicine Advances | Research Excellence Award

Associate Researcher | Zhongshan Hospital, Fudan University | China

Dr. Xiaoquan Huang is an accomplished clinical researcher whose work centers on gastroenterology, hepatology, metabolic liver disease, portal hypertension, gastrointestinal bleeding, and global disease epidemiology. With 848 Scopus citations, 79 publications, and an h-index of 13, his research demonstrates sustained impact across Health Sciences, Pharmacology & Toxicology, Cardiology, Endocrinology, Geriatrics, Neurology, Psychiatry, Pulmonary Medicine, Radiology, and related clinical domains. His research portfolio features high-quality journal publications in Chinese Medical Journal, Journal of Gastroenterology and Hepatology, Thrombosis and Haemostasis, Endoscopy, Liver International, Therapeutic Advances in Chronic Disease, and Journal of Translational Medicine. His works span clinical investigations, systematic reviews, global burden analyses, and translational studies addressing cirrhosis-related complications, portal vein thrombosis, metabolic-associated fatty liver disease, and early-onset colorectal cancer. Dr. Xiaoquan Huang has also served as a corresponding author on several influential global epidemiology studies focused on colorectal cancer and fatty liver disease burden.  Dr. Xiaoquan Huang’s scholarly contributions include research on variceal bleeding management, endoscopic innovations, thrombosis prediction markers, myeloproliferative neoplasm-associated portal hypertension, and gastrointestinal microbiome trends. His findings have advanced evidence-based approaches for cirrhotic complications, individualized treatment strategies, endoscopic therapy optimization, and risk stratification in liver disease. He has contributed to meta-analyses and systematic reviews, including work on transoral incisionless fundoplication (TIF) for GERD and therapeutic evaluations in portal hypertension, expanding global clinical understanding and practice guidelines. His research awards include multiple Young Investigator accolades from APDW, EASL, and JGHF, reflecting international recognition for innovation and research excellence. Dr. Xiaoquan Huang’s academic leadership includes reviewer service, conference presentations, and contributions to collaborative global research projects. His ongoing work continues to shape diagnostic, therapeutic, and epidemiological frameworks in hepatology and gastroenterology, establishing him as a significant contributor to clinical research and patient-centered innovations.

Profiles: Scopus | ORCID | ResearchGate | Sci Profiles

Featured Publications

1. Huang, X., Zou, D., Wang, H., Chen, W., Zhang, L., Li, F., Ma, L., Zhang, C., Chen, Y., & Chen, S. (2024). Gastric variceal obstruction improves the efficacy of endoscopic management of esophageal variceal bleeding in GOV type I. Endoscopy International Open, 12(8), E940–E946.

2. Wang, Y., Huang, X. (Corresponding author), Cheryala, M., Aloysius, M., Zheng, B., Yang, K., Chen, B., Fang, Q., Chowdary, S. B., Abougergi, M. S., & Chen, S. (2023). Global increase of colorectal cancer in young adults over the last 30 years: An analysis of the Global Burden of Disease Study 2019. Journal of Gastroenterology and Hepatology, 38(9), 1552–1558.

3. Jiang, S., Ai, Y., Fan, X., Huang, X. (Corresponding author), Wu, L., Ni, L., Li, F., & Chen, S. (2023). Increased factor VIII activity is predictive of the occurrence of portal vein thrombosis in cirrhosis. Thrombosis and Haemostasis, 123(7), 714–722.

4. Huang, X., Zhang, M., Ai, Y., Jiang, S., Xiao, M., Wang, L., Jian, Y., Zhuge, Y., Zhang, C., & Chen, S. (2022). Characteristics of myeloproliferative neoplasm-associated portal hypertension and endoscopic management of variceal bleeding. Therapeutic Advances in Chronic Disease, 13, Article 20406223221125691.

5. Huang, X., Abougergi, M. S., Sun, C., Murphy, D., Sondhi, V., Chen, B., Zheng, X., Chen, S., & Wang, Y. (2023). Incidence and outcomes of thromboembolic and bleeding events in patients with liver cirrhosis in the USA. Liver International, 43(2), 434–441.

Xiaofeng Dai | Medicine Advances | Best Researcher Award

Published on by New Scientists

Prof. Xiaofeng Dai | Medicine Advances | Best Researcher Award

Professor at The First Affiliated Hospital of Xi’an Jiaotong University, China.

Prof. Dr. Xiaofeng Dai is a distinguished expert in precision oncology and plasma medicine, currently serving as Professor and Research Theme Leader at the First Affiliated Hospital of Xi’an Jiaotong University. With dual PhDs in Systems Biology (Genetics) and Econo-Informatics from Finland, she integrates interdisciplinary knowledge across molecular oncology, bioinformatics, and translational medicine. Prof. Dai has established herself as a global leader in exploring the molecular and clinical applications of cold atmospheric plasma (CAP) therapy, publishing over 114 SCI-indexed articles with a cumulative impact factor of 806.74. She is the first or corresponding author of all these works, including four ESI highly cited papers. Her scientific achievements are further marked by 2 U.S. patents, 4 Chinese invention patents, and 10 software copyrights. She has secured and led national and industrial research funding exceeding 10 million RMB. Recognized for her pioneering work, Prof. Dai has received prestigious honors including Academician of the European Academy of Natural Sciences (2023), Outstanding Engineer Award (2022), and selection in the Jiangsu Province 333 High-level Talents Program (2024). As an active contributor to academic societies and a passionate educator, she is committed to translating advanced research into tangible clinical innovations.

Publication Profile

Scopus

Educational Details

  • Ph.D. in Econo-informatics, Aalto University, Finland (2016)

  • Ph.D. in Systems Biology – Genetics, Tampere University of Technology, Finland (2010)

  • M.Sc. in Bioinformatics, University of Tampere, Finland (2010)

  • M.Sc. in Molecular Biology, Chinese Academy of Agricultural Sciences, China (2006)

  • B.Sc. in Biotechnology, Central South University of Forestry and Technology, China (2003)

Professional Experience

  • 2023/06 – Present: Professor, Theme Leader – Precision Oncology, The First Affiliated Hospital of Xi’an Jiaotong University

  • 2017/06 – 2023/05: Professor, Theme Leader – Precision Medicine, Jiangnan University

  • 2014/02 – 2017/05: Associate Professor, Precision Medicine, Jiangnan University

  • 2016/12 – 2017/02: Visiting Scholar, Queensland University of Technology (QUT), Australia

  • 2013/10 – 2014/01: Principal Investigator, Chinese National Human Genome Center

  • 2011/02 – 2013/09: Senior Research Fellow, Helsinki University Central Hospital, Finland

  • 2010/02 – 2011/01: Senior Research Fellow, Institute for Molecular Medicine Finland

  • 2007/03 – 2011/01: Research Fellow, Tampere University of Technology, Finland

Research Interest

Prof. Dai’s research centers on cold atmospheric plasma (CAP)-based therapies in oncology and beyond. Her interests lie in exploring the molecular underpinnings of CAP’s selective cytotoxicity against malignant cells, investigating its influence on cancer stemness, metastasis, and tumor microenvironment. Expanding from cancer, her current work includes the use of CAP in immunomodulation, metabolic disorders, viral prevention, and vaccine enhancement. She also focuses on developing innovative CAP delivery systems such as ingestible CAP capsules and CAP-mediated photodynamic therapy, aiming to enhance its versatility and applicability. Prof. Dai is also addressing key translational barriers—such as CAP’s short-lived reactive components—by designing storage-stable and sustained-release solutions. Her research integrates bioinformatics, molecular biology, and plasma physics to decipher therapeutic pathways and identify CAP-mimicking biomolecules. Through computational modeling and synthetic chemistry, she is developing molecules with CAP-like efficacy, pushing forward the concept of molecular plasma medicine. Her goal is to create clinically adaptable, precision-targeted, and minimally invasive treatment solutions across a wide spectrum of diseases.

Research Skills

Prof. Dai is proficient in a broad array of interdisciplinary research techniques, spanning molecular biology, plasma physics, bioinformatics, and translational medicine. Her core expertise includes the design and execution of high-throughput omics experiments, real-time plasma-matter interaction studies, and in vitro/in vivo cancer models. She is skilled in CRISPR-based functional genomics, computational modeling of plasma-induced cellular responses, and RNA-seq data interpretation. Her strong background in systems biology enables her to construct multi-scale models that integrate molecular, cellular, and clinical data. She has extensive experience in developing biomedical devices and software tools tailored to plasma applications, backed by 10 software copyrights. Her ability to secure industrial partnerships and government funding demonstrates her leadership in translational research. Additionally, Prof. Dai has led cross-disciplinary teams to develop CAP-based interventions for autoimmune diseases, metabolic disorders, and infectious disease prevention. She is also adept at scientific communication, grant writing, project management, and mentoring junior researchers and students.

Awards and Honors

Prof. Dai’s research excellence and leadership have been widely recognized. In 2024, she was named a Level 3 recipient in the prestigious “333 High-Level Talent Program” of Jiangsu Province. In 2023, she was elected an Academician of the European Academy of Natural Sciences, highlighting her international stature. Her innovative research earned her the Outstanding Engineer Young Award in 2022 from the International Scientific Exchange Foundation of China. Earlier honors include being a member of the Dual Innovative Team of Jiangsu Province (2017), receiving the Six Talent Peaks Award (2016), and being named a Leading Talent for Social Undertakings in Wuxi (2015). These accolades underscore her sustained contributions to scientific innovation, particularly in the interdisciplinary domains of bioengineering, oncology, and plasma medicine. They also reflect recognition by both national and international academic bodies, industry collaborators, and government agencies. Her ability to integrate science, education, and clinical translation has made her a respected figure in China’s high-impact research ecosystem.

Author Metrics

  • Total Citations: 4,522

  • Citations by Documents: 4,063

  • Total Publications (Documents): 125

  • h-index: 29

Top Noted Publication

1. Advanced Science (2020)

Title: Innovative precision gene-editing tools in personalized cancer medicine
Journal: Advanced Science

  • IF (2023): ~17.5

  • JCR Rank: Q1 (Multidisciplinary Sciences)

  • Reason: Highly impactful, interdisciplinary, cutting-edge gene-editing research published in a top-tier journal.

2. Trends in Biotechnology (2018)

Title: The emerging role of gas plasma in oncotherapy
Journal: Trends in Biotechnology

  • IF (2023): ~20.0

  • JCR Rank: Q1 (Biotechnology & Applied Microbiology)

  • Reason: Published in a Cell Press journal, which is highly selective. Recognized for trend-setting reviews.

3. Signal Transduction and Targeted Therapy (2025)

Title: Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics
Journal: Signal Transduction and Targeted Therapy

  • IF (2023): ~39.3

  • JCR Rank: Q1 (Immunology/Oncology)

  • Reason: Nature Publishing Group journal with very high impact. Although recent, its publication in a Nature journal signifies top-tier status.

4. Trends in Genetics (2022)

Title: Histone lactylation: epigenetic mark of glycolytic switch
Journal: Trends in Genetics

  • IF (2023): ~12.0

  • JCR Rank: Q1 (Genetics & Heredity)

  • Reason: Cell Press review journal with major influence in the field of epigenetics and gene regulation.

5. Biotechnology Advances (2019)

Title: Standardizing CAR-T therapy: getting it scaled up
Journal: Biotechnology Advances

  • IF (2023): ~14.2

  • JCR Rank: Q1 (Biotechnology)

  • Reason: Authoritative journal in biotechnology with strong clinical and commercial relevance, especially in CAR-T research.

Conclusion

Prof. Dr. Xiaofeng Dai is a leading interdisciplinary scientist advancing cold atmospheric plasma (CAP) therapy in precision oncology and regenerative medicine. With dual Ph.D. degrees, over 100 SCI-indexed publications, and multiple patents, she bridges molecular research with clinical application. Her leadership in securing major research funding and fostering industry collaboration highlights her impact across science and innovation. As an educator and mentor, she is shaping future experts in cancer biology and bioinformatics. Through national and international partnerships, Prof. Dai remains at the forefront of translating high-impact research into real-world medical solutions.